Close Menu
Home » All of Us Program Working on IDE Submission to FDA, Weighing Long-Read Sequencing Techs

All of Us Program Working on IDE Submission to FDA, Weighing Long-Read Sequencing Techs

Oct 24, 2019
|
Julia Karow
Premium

This article has been updated to clarify that the All of Us program still intends to use genotyping arrays on all participants to generate data for research and for returning non-health-related results.

NEW YORK – The National Institutes of Health's All of Us research program is working on an investigational device exemption (IDE) submission to the US Food and Drug Administration to return results to participants next year and is adjusting the mix of genomic technologies to generate data for its study cohort.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Project to Discuss Race and Genetics in Class

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

Taking It All On

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

PLOS Papers on ASD-Related Syndrome, Twin Gut Microbiomes, Zika Virus Evolution

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

Unexpected Close

GenomeWeb reports that Veritas Genetics is suspending its US operations.

Dec
10
Featured Webinar

Maximizing Diagnostic Yield with an Optimized Variant Interpretation Platform

Sponsored by
Congenica II

This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.

Dec
11
Featured Webinar

Advances in Precision Oncology: Tertiary Analysis Software for Solid Tumor NGS

Sponsored by
Roche

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.

Dec
17
Featured Webinar

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

What's Popular?

In Sequencing

  1. Adaptive Biotechnologies, AbbVie Partner on MRD Testing in Multiple Myeloma Drug Trials

  2. Veritas Genetics Halts US Operations, Lays Off More Than 30

  3. Gene Panel Finds Pathogenic Variants Missed by Standard Tests in 5 Percent of Familial Cancer Cases

  4. Illumina, PacBio Dispute UK Regulator's Finding That Merger Would Weaken Competition

  5. High-Throughput Single-Cell Transcriptomics Assay Facilitates Compound Screens

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.